Tag: KRAS inhibitor
New Drug Daraxonrasib Nearly Doubles Pancreatic Cancer Survival in Phase 3 Trial
Daraxonrasib nearly doubles survival in advanced pancreatic cancer patients with KRAS G12C mutations. The breakthrough targets a previously "undruggable" protein…
Submit Your Paper to GMJ
No APC until January 2027.